Preventive Reminder Ordering AssistanCe Via Texting for Improved Visit Encounters (PROACTIVE)
A substantial portion of the United States population remains overdue for key screenings, despite availability and insurance coverage of preventive health services. Barriers for completion and remaining up to date with screening include patients not remaining actively engaged with their care team, time constraints during office visits, and operational strain. This project aims to implement and evaluate a primary care visit-based program that harmonizes multiple preventive health and chronic disease management care gaps, reduces staff burden, and improves ordering and subsequent patient follow through on completion of overdue care gaps.
In this study, the investigators will evaluate nudges to clinicians and patients to help increase screening completion for multiple care gaps identified as high priority by primary care, including imaging (Mammogram, DEXA) and labs (Diabetes Management (Hemoglobin A1C, Basic Metabolic Panel, and Urine Microalbumin), Hepatitis C, and Lipids). This will be a 6 month, stepped-wedge, pragmatic trial conducted at Penn Medicine.
調査の概要
状態
条件
詳細な説明
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania Health System
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
All patients must meet the following criteria to be eligible:
- 18 years or older
- A scheduled new or return (non-urgent/sick) primary care visit at one of the study practices
- Overdue for at least one of the included care gaps according to Health Maintenance: Mammogram, DEXA, Hemoglobin A1C, Basic Metabolic Panel, Urine Microalbumin, Lipids, Hepatitis C
- Last eligible office visit was greater than or equal to 3 months ago
Exclusion Criteria:
As this trial is integrated with routine clinical operations, there will be no exclusion criteria. However, for each care gap independently, we will exclude all patient visits throughout the remaining trial duration after the patient's first eligible office visit within the trial duration. In other words, each patient will contribute data from at most one eligible office visit.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし:Control Condition
During the control condition, clinics will receive standard of care.
|
|
|
実験的:Active Intervention
During the active intervention, clinics will receive both clinician and patient facing nudges.
Patient nudges will be pre- and post-visit text message reminders about their overdue care gaps.
Clinician nudges will be default pended orders for overdue care gaps and an EHR Smart Data Element communication banner notifying the provider that a pre-visit reminder was sent to the patient and that orders have been pended for their review.
|
The patient nudges will be delivered by a series of one to three text messages.
Patients will receive the pre-visit text message 2 days prior to their scheduled primary care visit.
This message will remind them that they are overdue for their preventive care imaging and/or labs and encourage them to speak with their provider about screening completion during their upcoming appointment.
All patients who complete their primary care visit and whose provider signed at least one of their pended orders will be sent post-visit text messages 7 and 14 days after completion, if they have not yet scheduled or completed their overdue labs and/or imaging.
The messages delivered at 7 and 14 days will remind patients that appointments for lab and imaging are available for them and provide phone number(s) to call for scheduling and a link to complete scheduling online.
Patients will also have the option to engage with a bi-directional support menu via text message.
The default pended orders will be automatically placed into the patient's primary care visit encounter via a custom Epic extension for each included care gap (mammogram, DEXA, hemoglobin A1C, basic metabolic panel, urine microalbumin, lipids, and Hepatitis C) that the patient is overdue for according to their Health Maintenance status.
Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
An electronic health record (EHR) communication will be visible to the provider and entire care team during the visit encounter.
This smart data element (SDE) communication will display in the patient's EHR encounter as a section in pre-charting, check-in, and rooming, and will notify the clinician and care team that a pre-visit communication was sent to the patient regarding their overdue status for their preventive care imaging and/or labs.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Mammogram Screening Completion (3 months)
時間枠:Within 3 months after first eligible primary care visit.
|
The primary outcome is the proportion of patients overdue who complete a mammogram within 3 months after the first eligible primary care visit.
|
Within 3 months after first eligible primary care visit.
|
|
Hepatitis C Screening Completion (3 months)
時間枠:Within 3 months after first eligible primary care visit.
|
The primary outcome is the proportion of patients overdue who complete Hepatitis C screening within 3 months after the first eligible primary care visit.
|
Within 3 months after first eligible primary care visit.
|
|
Lipids Screening Completion (3 months)
時間枠:Within 3 months after first eligible primary care visit.
|
The primary outcome is the proportion of patients overdue who complete lipids screening within 3 months after the first eligible primary care visit.
|
Within 3 months after first eligible primary care visit.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
DEXA Screening Completion (3 months)
時間枠:Within 3 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete DEXA screening within 3 months after the first eligible primary care visit.
|
Within 3 months after the first eligible primary care visit.
|
|
Hemoglobin A1C Screening Completion (3 months)
時間枠:Within 3 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Hemoglobin A1C screening within 3 months after the first eligible primary care visit.
|
Within 3 months after the first eligible primary care visit.
|
|
Basic Metabolic Panel Screening Completion (3 months)
時間枠:Within 3 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Basic Metabolic Panel screening within 3 months after the first eligible primary care visit.
|
Within 3 months after the first eligible primary care visit.
|
|
Urine Microalbumin Screening Completion (3 months)
時間枠:Within 3 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Urine Microalbumin screening within 3 months after the first eligible primary care visit.
|
Within 3 months after the first eligible primary care visit.
|
|
Mammogram Screening Completion (6 months)
時間枠:Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete a mammogram within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
Hepatitis C Screening Completion (6 months)
時間枠:Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Hepatitis C screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
Lipids Screening Completion (6 months)
時間枠:Within 6 months after the first eligible primary care visit.
|
The primary outcome is the proportion of patients overdue who complete lipids screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
DEXA Screening Completion (6 months)
時間枠:Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete DEXA screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
Hemoglobin A1C Screening Completion (6 months)
時間枠:Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Hemoglobin A1C screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
Basic Metabolic Panel Screening Completion (6 months)
時間枠:Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Basic Metabolic Panel screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
Urine Microalbumin Screening Completion (6 months)
時間枠:Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Urine Microalbumin screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
協力者と研究者
捜査官
- 主任研究者:Shivan Mehta、University of Pennsylvania
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。